David R. Bauer
Lawyers
Filters
Stoke Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc.,…
Orchard Therapeutics plc Approximately $128 Million Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $128 million follow-on offering by Orchard Therapeutics…
Applied Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering of common stock of Applied Therapeutics, Inc. Applied…
Intercept Pharmaceuticals, Inc. Concurrent $231 Million Common Stock Offering and $230 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 2,760,000 shares of common stock of Intercept Pharmaceuticals, Inc. …
NGM Biopharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…
Magenta Therapeutics, Inc. $64.8 Million Follow-On Offering of Common Stock
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $64.8 million follow-on offering of common stock of Magenta Therapeutics,…
TransMedics Group, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $104.7 million initial public offering of 6,543,500 shares of common stock of TransMedics Group, Inc.,…
Millendo Therapeutics, Inc. SEC-Registered At-The-Market Offering Program
Davis Polk advised a sales agent in connection with the establishments of an SEC-registered at-the-market offering program by Millendo Therapeutics, Inc. of up to $50 million gross…
Davis Polk Advises ShockWave Medical, Inc. on Its $111.4 Million Initial Public Offering
Davis Polk advised ShockWave Medical, Inc. on its SEC-registered initial public offering of 6,555,000 shares of common stock for an aggregate price to the public of approximately $111.4…
Horizon Pharma Follow-On Offering
Davis Polk advised the underwriters in connection with the $345 million public offering of ordinary shares of Horizon Pharma plc. Horizon’s ordinary shares are listed on the NASDAQ Global…